ARTICLE | Clinical News

EchoGen Emulsion which uses PhaseShift technology to convert liquid emulsion into gas microbubbles in the bloodstream data

April 3, 1995 7:00 AM UTC

The Bothell, Wash., company announced Phase II results in 59 patients, showing significantly increased visualization of blood flow and tumors.

The contrast agent showed a sensitivity of 96 percent and a specificity of 93 percent. The number of patients who were found to have lesions was significantly increased (p=0.046), with a changed diagnosis for 12 percent of the patients. ...